CLPT
ClearPoint Neuro, Inc. NASDAQ$11.18
Mkt Cap $335.2M
52w Low $8.27
13.3% of range
52w High $30.10
50d MA $10.63
200d MA $14.05
P/E (TTM)
-12.6x
EV/EBITDA
-18.2x
P/B
11.5x
Debt/Equity
2.1x
ROE
-91.1%
P/FCF
-15.8x
RSI (14)
—
ATR (14)
—
Beta
1.18
50d MA
$10.63
200d MA
$14.05
Avg Volume
761.7K
About
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the in…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | AMC | -0.22 | -0.27 | -22.7% | 11.16 | -4.1% | -13.9% | -17.7% | -19.1% | -14.8% | -15.6% | -5.9% | — |
| Nov 6, 2025 | AMC | -0.20 | -0.21 | -5.0% | 18.23 | -17.9% | -13.3% | -9.3% | -4.6% | -8.3% | -15.0% | -24.9% | — |
| Aug 12, 2025 | AMC | -0.20 | -0.21 | -5.0% | 10.54 | +1.6% | +13.1% | +10.8% | +9.6% | +6.5% | -0.8% | +5.2% | — |
| May 13, 2025 | AMC | -0.15 | -0.22 | -46.7% | 14.20 | -12.0% | -12.5% | -9.0% | -7.2% | -7.6% | -9.9% | -14.9% | — |
| Feb 26, 2025 | AMC | -0.15 | -0.20 | -33.3% | 17.22 | -7.1% | -17.5% | -15.7% | -21.3% | -22.1% | -17.7% | -30.5% | — |
| Nov 7, 2024 | AMC | -0.17 | -0.18 | -5.9% | 13.42 | -6.8% | -13.2% | -15.0% | -17.1% | -18.4% | -16.2% | +9.2% | — |
| Aug 7, 2024 | AMC | -0.19 | -0.16 | +15.8% | 6.44 | +19.4% | +40.7% | +37.9% | +51.9% | +53.9% | +52.6% | +84.6% | — |
| May 7, 2024 | AMC | -0.19 | -0.16 | +15.8% | 5.89 | +9.5% | +1.7% | +3.7% | -0.5% | -0.7% | +2.0% | -2.5% | — |
| Mar 12, 2024 | AMC | -0.22 | -0.19 | +13.6% | 6.05 | +12.6% | +18.5% | +19.2% | +18.2% | +16.9% | +15.4% | +2.5% | — |
| Nov 9, 2023 | AMC | -0.25 | -0.20 | +20.0% | 5.42 | -1.8% | -17.7% | -15.7% | -7.0% | -8.9% | -3.0% | +17.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | B. Riley Securities | Maintains | Buy → Buy | — | $11.16 | $10.70 | -4.1% | -13.9% | -17.7% | -19.1% | -14.8% | -15.6% |
| Mar 5 | B. Riley Securities | Maintains | Buy → Buy | — | $8.94 | $8.99 | +0.6% | +3.5% | +11.9% | +29.1% | +26.6% | +30.0% |
| Aug 1 | Stifel | Maintains | Buy → Buy | — | $10.40 | $10.12 | -2.7% | -3.8% | +1.2% | +1.2% | +3.8% | +5.0% |
| Apr 25 | B. Riley Securities | Maintains | Buy → Buy | — | $14.29 | $14.34 | +0.3% | +2.9% | +2.9% | +2.7% | +0.7% | -2.7% |
| Apr 1 | Stifel | Maintains | Buy → Buy | — | $11.89 | $12.17 | +2.4% | +10.1% | +10.1% | +2.1% | -7.2% | -7.9% |
| Jan 28 | B. Riley Securities | Maintains | Buy → Buy | — | $17.00 | $17.82 | +4.8% | +5.5% | +4.6% | +3.6% | +2.7% | -0.3% |
| Jan 21 | Lake Street | Maintains | Buy → Buy | — | $15.04 | $16.00 | +6.4% | +22.5% | +19.1% | +18.2% | +18.7% | +13.0% |
| Aug 27 | Lake Street | Maintains | Buy → Buy | — | $11.70 | $12.14 | +3.8% | +9.0% | +7.4% | +12.6% | +10.9% | +7.9% |
| Mar 13 | Stifel | Maintains | Buy → Buy | — | $6.05 | $6.81 | +12.6% | +18.5% | +19.2% | +18.2% | +16.9% | +15.4% |
| Aug 9 | Lake Street | Maintains | Buy → Buy | — | $6.40 | $6.40 | +0.0% | -2.8% | -4.1% | -6.7% | -3.3% | -6.2% |
Recent Filings
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Clearpoint Health (CLPT) disclosed material information via press release and investor presentation on March 17, 2026, potentially signaling major business updates or earnings guidance that could significantly impact stock valuation and investor sentiment.
Mar 17
8-K
ClearPoint Neuro, Inc. -- 8-K Filing
ClearPoint Neuro completed an acquisition and is filing financial statements of the acquired business, indicating the company is expanding its neurotech portfolio through an M&A transaction.
Feb 5
Data updated apr 25, 2026 1:46am
· Source: massive.com